GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » PS Ratio
中文

Arcutis Biotherapeutics (Arcutis Biotherapeutics) PS Ratio

: 9.80 (As of Today)
View and export this data going back to 2020. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arcutis Biotherapeutics's share price is $8.74. Arcutis Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.89. Hence, Arcutis Biotherapeutics's PS Ratio for today is 9.80.

The historical rank and industry rank for Arcutis Biotherapeutics's PS Ratio or its related term are showing as below:

ARQT' s PS Ratio Range Over the Past 10 Years
Min: 2.4   Med: 51.47   Max: 1472.31
Current: 9.86

During the past 7 years, Arcutis Biotherapeutics's highest PS Ratio was 1472.31. The lowest was 2.40. And the median was 51.47.

ARQT's PS Ratio is ranked worse than
54.08% of 993 companies
in the Biotechnology industry
Industry Median: 8.93 vs ARQT: 9.86

Arcutis Biotherapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.15. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.89.

During the past 12 months, the average Revenue per Share Growth Rate of Arcutis Biotherapeutics was 1183.60% per year.

Back to Basics: PS Ratio


Arcutis Biotherapeutics PS Ratio Historical Data

The historical data trend for Arcutis Biotherapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcutis Biotherapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - - 220.90 3.76

Arcutis Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 220.90 102.80 49.90 6.68 3.76

Competitive Comparison

For the Biotechnology subindustry, Arcutis Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcutis Biotherapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's PS Ratio falls into.



Arcutis Biotherapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Arcutis Biotherapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=8.74/0.892
=9.80

Arcutis Biotherapeutics's Share Price of today is $8.74.
Arcutis Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Arcutis Biotherapeutics  (NAS:ARQT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Arcutis Biotherapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Executives
Masaru Matsuda officer: SVP and General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Larry Todd Edwards officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick Burnett officer: See Remarks C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Todd Franklin Watanabe director, officer: President and CEO C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Howard G. Welgus director C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney officer: Senior VP, Manufacturing C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne officer: Chief Technical Officer
Kenneth A. Lock officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Matthew Richard Moore officer: SVP and Chief Business Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan director 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656